Genmab — April 2025
-
New Chromatography Data Platform Wins Bio-IT World Award for Genmab and Genedata https://www.prweb.com/releases/new-chromatography-data-platform-wins-bio-it-world-award-for-genmab-and-genedata-302419340.html
-
Cancer Control Month https://x.com/AlbertBourla/status/1908189760977318280?t=X6MVXNiytQbn6g_tBGnbjQ&s=19
-
Godmorgen
-
from the Genedata website you can find they work with all major players https://www.genedata.com/customers/meet-our-customers , so I think it is fair to say that such an award is somewhat of a testimonial of Genmab's innovative strength. This is a Genmab case from that page https://www.genedata.com/fileadmin/4.Resources/Case-studies/Ex_Genmab_BispecificABs_19E12.pdf
-
https://www.dnb.no/seg-fundamental/fundamentalweb/inst/GetReport.aspx?file=CMP4_254575.pdf&uid=1154&auth=2jMoUXPS1%2FJy8ZNikSg5XXKm0kY%3D&pwd=&popup=n I don't think this Research report from DNB Markets from last month was posted yet
-
Så er der sgu snart aktier til en tusse!
-
European Commission approves Johnson & Johnson’s subcutaneous DARZALEX
(daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility -CEPHEUS
https://www.globenewswire.com/news-release/2025/04/07/3056498/0/en/European-Commission-approves-Johnson-Johnson-s-subcutaneous-DARZALEX-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regard.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind